{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-040276","form_type":"8-K","ticker":"QCLS","cik":"0001321834","company_name":"Q/C TECHNOLOGIES, INC.","filed_at":"2024-10-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.087677+00:00","generated_at":"2026-05-30T19:05:05.458502+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"TNF Pharma raises $600k via private placement at 20% premium; CRO partner engaged","bullets":["Sold 283,019 shares at $2.12/share (120% of 30-day VWAP) to Prevail Partners, gross proceeds $600k.","Proceeds for working capital; may be used to pay Prevail InfoWorks invoices under an August 2024 services agreement.","Prevail InfoWorks engaged as CRO for upcoming Phase 2 sarcopenia/frailty study of MYMD-1 TNFα inhibitor.","Press release states company is fully funded for clinical trials for next two years.","MYMD-1 previously met primary endpoints in a small Phase 2 sarcopenia study (2023) reducing chronic inflammatory markers."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-040276","json":"https://secwatch.observer/filing/0001493152-24-040276.json","markdown":"https://secwatch.observer/filing/0001493152-24-040276.md","text":"https://secwatch.observer/filing/0001493152-24-040276.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1321834/000149315224040276/0001493152-24-040276-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1321834/000149315224040276/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T19:05:05.458502+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}